(0.24%) 5 112.17 points
(0.23%) 38 328 points
(0.23%) 15 965 points
(-1.43%) $82.65
(4.26%) $2.01
(-0.12%) $2 344.50
(-0.10%) $27.51
(3.73%) $956.50
(-0.17%) $0.933
(-0.24%) $11.00
(-0.45%) $0.797
(1.75%) $93.48
2.40% $ 0.183
Live Chart Being Loaded With Signals
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology...
Stats | |
---|---|
Dzisiejszy wolumen | 383 226 |
Średni wolumen | 1.58M |
Kapitalizacja rynkowa | 45.95M |
EPS | $0 ( 2024-03-27 ) |
Następna data zysków | ( $-0.0300 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.670 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-15 | Matkovits Theresa | Buy | 1 300 000 | Stock Option (right to Buy) |
2023-12-15 | Hoover Thomas | Buy | 1 000 000 | Stock Option (right to Buy) |
2023-12-15 | Kucinski Keith A | Buy | 1 000 000 | Stock Option (right to Buy) |
2023-12-15 | Liu Hui | Buy | 1 000 000 | Stock Option (right to Buy) |
2023-12-15 | Jabbour Jerome D | Buy | 3 500 000 | Stock Option (right to Buy) |
INSIDER POWER |
---|
97.71 |
Last 97 transactions |
Buy: 33 257 124 | Sell: 4 123 116 |
Wolumen Korelacja
Matinas BioPharma Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Matinas BioPharma Korelacja - Waluta/Towar
Matinas BioPharma Finanse
Annual | 2023 |
Przychody: | $1.10M |
Zysk brutto: | $155 000 (14.14 %) |
EPS: | $-0.110 |
FY | 2023 |
Przychody: | $1.10M |
Zysk brutto: | $155 000 (14.14 %) |
EPS: | $-0.110 |
FY | 2022 |
Przychody: | $3.19M |
Zysk brutto: | $-13.49M (-423.15 %) |
EPS: | $-0.0600 |
FY | 2021 |
Przychody: | $33.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.110 |
Financial Reports:
No articles found.
Matinas BioPharma
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej